Hara K, Saito A, Shigeno Y, Kohno S, Ishikawa K, Kato Y, Kikuchi K, Yamamoto A, Hiraga Y, Oizumi K
Jpn J Antibiot. 1986 Nov;39(11):2926-37.
Intravenous drip infusion of a new aminoglycoside agent, astromicin (ASTM), was used against various infections in the field of internal medicine, and its clinical efficacy and safety were studied. Clinical effects were evaluated in 105 among 111 patients administered with ASTM. Almost all the patients were given 200 mg of ASTM twice a day by intravenous drip infusion for 60 minutes. Among 105 cases, clinical effects of ASTM were excellent in 15, good in 56, fair in 10 and poor in 24. The number of cases who were judged as excellent or good was 71, and the efficacy rate was 67.6%. Efficacy rates classified by diseases were as follows; 80% (4/5 cases) in sepsis, 55.6% (5/9 cases) in urinary tract infections, and 68.1 (62/91 cases) in respiratory tract infections (RTI). In 91 cases with RTI, clinical effects of ASTM were excellent in 14, good in 48, fair in 9 and poor in 20. The efficacy rates classified by diseases of RTI were 77.3% (34/44 cases) in pulmonary parenchyma infection and 59.6% (28/47 cases) in chronic RTI and others. As subjective and objective side effects, tinnitus and malaise were observed in 5 (4.5%) of 110 patients evaluated for side effects. But, either symptom was mild and disappeared after the end or withdrawal of administration. Slight elevations of S-GPT, BUN and others were observed in 7 cases (6.4%) as abnormal laboratory test values. Safety and efficacy of intravenous drip infusion of ASTM were confirmed.
静脉滴注新型氨基糖苷类药物阿司米星（ASTM）用于治疗内科领域的各种感染，并对其临床疗效和安全性进行了研究。在111例接受ASTM治疗的患者中，对105例患者的临床效果进行了评估。几乎所有患者均通过静脉滴注给予200mg ASTM，每日2次，持续60分钟。在105例患者中，ASTM的临床效果为优15例，良56例，中10例，差24例。判定为优或良的病例数为71例，有效率为67.6%。按疾病分类的有效率如下：败血症为80%（4/5例），尿路感染为55.6%（5/9例），呼吸道感染（RTI）为68.1%（62/91例）。在91例RTI患者中，ASTM的临床效果为优14例，良48例，中9例，差20例。RTI按疾病分类的有效率在肺实质感染中为77.3%（34/44例），在慢性RTI及其他情况中为59.6%（28/47例）。作为主观和客观副作用，在110例接受副作用评估的患者中，有5例（4.5%）出现耳鸣和不适。但两种症状均较轻，在给药结束或停药后消失。7例（6.4%）患者的实验室检查值出现S-GPT、BUN等轻度升高，作为异常值。证实了ASTM静脉滴注的安全性和有效性。
